Total Funding
52
43
Total FundingPost-IPO Equity raised
Growth Score
-8 pts
Heat Score
-3 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
155863
TAO Synergies is a clinical-stage biopharmaceutical company that develops novel therapies for neurodegenerative diseases.
James Altucher: lead TAOPast Role: The Wall Street Journal, Writer- Robert Weinstein: Chief Financial Officer
About the Company
TAO Synergies is a clinical-stage biotech company leveraging Bryostatin-1 and its analogs to discover and develop targeted therapeutics for neurodegenerative diseases and developmental disorders. The company has targeted Bryostatin-1 due to its high potential and multi-modal efficacy: through protein kinase C (PKCϵ) activation, Bryostatin-1
stimulates synaptic growth factors, amyloid-β degrading enzymes, as well as prevents Tau transformation into neurofibrillary tangles.
